The Cost of Treating Cancer
When you crunch the numbers on drug development, are the costs of cancer drugs justified?
Roisin McGuigan |
The road to creating a new cancer drug is long and winding, and paved with expensive R&D. But just how much money and time does it really take? The cost of anticancer therapies is continuing to rise, and the huge expense of bringing a new drug to market is often cited as the reason. Two US researchers decided to take a closer look at the claim, by analyzing the data on ten publicly traded drug companies. They chose companies with only one drug currently approved by the FDA, but also took into account the money the companies had spent on other drugs that ultimately didn’t gain approval.
Read the full article now
Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE and always will be!